High-dose intravenous corticosteroids for ocular inflammatory diseases

Leon D. Charkoudian, Gui Shuang Ying, Siddharth S. Pujari, Sapna Gangaputra, Jennifer Thorne, C. Stephen Foster, Douglas A. Jabs, Grace A. Levy-Clarke, Robert B. Nussenblatt, James T. Rosenbaum, Eric B. Suhler, John H. Kempen

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the effectiveness and risk of complications of high-dose intravenous pulsed corticosteroids for noninfectious ocular inflammatory diseases. Methods: Retrospective cohort study in which 104 eyes of 70 patients who received high-dose intravenous corticosteroids for treatment of active ocular inflammation were identified from five centers. The main outcome measures were control of inflammation and occurrence of ocular or systemic complications within 1 month after treatment. Results: Within ≤1 month of starting treatment, 57% of eyes achieved complete control of inflammation (95% confidence interval (CI): 3383%), improving to 82% when near-complete control was included (95% CI: 6196%). Most eyes (85%; 95% CI: 7095%) gained clinically significant improvement in anterior chamber inflammation. One patient developed a colon perforation during treatment. No other major complications were recorded. Conclusions: Treatment of ocular inflammation with high-dose intravenous corticosteroids resulted in substantial clinical improvement for most cases within 1 month. Complications of therapy were infrequent.

Original languageEnglish (US)
Pages (from-to)91-99
Number of pages9
JournalOcular Immunology and Inflammation
Volume20
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Eye Diseases
Adrenal Cortex Hormones
Inflammation
Confidence Intervals
Therapeutics
Anterior Chamber
Colon
Cohort Studies
Retrospective Studies
Outcome Assessment (Health Care)

Keywords

  • Corticosteroids
  • Inflammation
  • Intravenous
  • Noninfectious
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy

Cite this

Charkoudian, L. D., Ying, G. S., Pujari, S. S., Gangaputra, S., Thorne, J., Foster, C. S., ... Kempen, J. H. (2012). High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocular Immunology and Inflammation, 20(2), 91-99. https://doi.org/10.3109/09273948.2011.646382

High-dose intravenous corticosteroids for ocular inflammatory diseases. / Charkoudian, Leon D.; Ying, Gui Shuang; Pujari, Siddharth S.; Gangaputra, Sapna; Thorne, Jennifer; Foster, C. Stephen; Jabs, Douglas A.; Levy-Clarke, Grace A.; Nussenblatt, Robert B.; Rosenbaum, James T.; Suhler, Eric B.; Kempen, John H.

In: Ocular Immunology and Inflammation, Vol. 20, No. 2, 04.2012, p. 91-99.

Research output: Contribution to journalArticle

Charkoudian, LD, Ying, GS, Pujari, SS, Gangaputra, S, Thorne, J, Foster, CS, Jabs, DA, Levy-Clarke, GA, Nussenblatt, RB, Rosenbaum, JT, Suhler, EB & Kempen, JH 2012, 'High-dose intravenous corticosteroids for ocular inflammatory diseases', Ocular Immunology and Inflammation, vol. 20, no. 2, pp. 91-99. https://doi.org/10.3109/09273948.2011.646382
Charkoudian, Leon D. ; Ying, Gui Shuang ; Pujari, Siddharth S. ; Gangaputra, Sapna ; Thorne, Jennifer ; Foster, C. Stephen ; Jabs, Douglas A. ; Levy-Clarke, Grace A. ; Nussenblatt, Robert B. ; Rosenbaum, James T. ; Suhler, Eric B. ; Kempen, John H. / High-dose intravenous corticosteroids for ocular inflammatory diseases. In: Ocular Immunology and Inflammation. 2012 ; Vol. 20, No. 2. pp. 91-99.
@article{6e6567eb756349eabccda01c8eeca52e,
title = "High-dose intravenous corticosteroids for ocular inflammatory diseases",
abstract = "Purpose: To evaluate the effectiveness and risk of complications of high-dose intravenous pulsed corticosteroids for noninfectious ocular inflammatory diseases. Methods: Retrospective cohort study in which 104 eyes of 70 patients who received high-dose intravenous corticosteroids for treatment of active ocular inflammation were identified from five centers. The main outcome measures were control of inflammation and occurrence of ocular or systemic complications within 1 month after treatment. Results: Within ≤1 month of starting treatment, 57{\%} of eyes achieved complete control of inflammation (95{\%} confidence interval (CI): 3383{\%}), improving to 82{\%} when near-complete control was included (95{\%} CI: 6196{\%}). Most eyes (85{\%}; 95{\%} CI: 7095{\%}) gained clinically significant improvement in anterior chamber inflammation. One patient developed a colon perforation during treatment. No other major complications were recorded. Conclusions: Treatment of ocular inflammation with high-dose intravenous corticosteroids resulted in substantial clinical improvement for most cases within 1 month. Complications of therapy were infrequent.",
keywords = "Corticosteroids, Inflammation, Intravenous, Noninfectious, Uveitis",
author = "Charkoudian, {Leon D.} and Ying, {Gui Shuang} and Pujari, {Siddharth S.} and Sapna Gangaputra and Jennifer Thorne and Foster, {C. Stephen} and Jabs, {Douglas A.} and Levy-Clarke, {Grace A.} and Nussenblatt, {Robert B.} and Rosenbaum, {James T.} and Suhler, {Eric B.} and Kempen, {John H.}",
year = "2012",
month = "4",
doi = "10.3109/09273948.2011.646382",
language = "English (US)",
volume = "20",
pages = "91--99",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - High-dose intravenous corticosteroids for ocular inflammatory diseases

AU - Charkoudian, Leon D.

AU - Ying, Gui Shuang

AU - Pujari, Siddharth S.

AU - Gangaputra, Sapna

AU - Thorne, Jennifer

AU - Foster, C. Stephen

AU - Jabs, Douglas A.

AU - Levy-Clarke, Grace A.

AU - Nussenblatt, Robert B.

AU - Rosenbaum, James T.

AU - Suhler, Eric B.

AU - Kempen, John H.

PY - 2012/4

Y1 - 2012/4

N2 - Purpose: To evaluate the effectiveness and risk of complications of high-dose intravenous pulsed corticosteroids for noninfectious ocular inflammatory diseases. Methods: Retrospective cohort study in which 104 eyes of 70 patients who received high-dose intravenous corticosteroids for treatment of active ocular inflammation were identified from five centers. The main outcome measures were control of inflammation and occurrence of ocular or systemic complications within 1 month after treatment. Results: Within ≤1 month of starting treatment, 57% of eyes achieved complete control of inflammation (95% confidence interval (CI): 3383%), improving to 82% when near-complete control was included (95% CI: 6196%). Most eyes (85%; 95% CI: 7095%) gained clinically significant improvement in anterior chamber inflammation. One patient developed a colon perforation during treatment. No other major complications were recorded. Conclusions: Treatment of ocular inflammation with high-dose intravenous corticosteroids resulted in substantial clinical improvement for most cases within 1 month. Complications of therapy were infrequent.

AB - Purpose: To evaluate the effectiveness and risk of complications of high-dose intravenous pulsed corticosteroids for noninfectious ocular inflammatory diseases. Methods: Retrospective cohort study in which 104 eyes of 70 patients who received high-dose intravenous corticosteroids for treatment of active ocular inflammation were identified from five centers. The main outcome measures were control of inflammation and occurrence of ocular or systemic complications within 1 month after treatment. Results: Within ≤1 month of starting treatment, 57% of eyes achieved complete control of inflammation (95% confidence interval (CI): 3383%), improving to 82% when near-complete control was included (95% CI: 6196%). Most eyes (85%; 95% CI: 7095%) gained clinically significant improvement in anterior chamber inflammation. One patient developed a colon perforation during treatment. No other major complications were recorded. Conclusions: Treatment of ocular inflammation with high-dose intravenous corticosteroids resulted in substantial clinical improvement for most cases within 1 month. Complications of therapy were infrequent.

KW - Corticosteroids

KW - Inflammation

KW - Intravenous

KW - Noninfectious

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=84858181504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858181504&partnerID=8YFLogxK

U2 - 10.3109/09273948.2011.646382

DO - 10.3109/09273948.2011.646382

M3 - Article

VL - 20

SP - 91

EP - 99

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 2

ER -